Livtencity Approved for Post-Transplant Cytomegalovirus Infection
Livtencity is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates.
Hematopoietic Stem Cell Transplantation
Autologous HSCT Provides Long-Term Survival Benefit in Mantle Cell Lymphoma
Transplant improved progression-free and overall survival at a median follow-up of 14 years.
An Analysis of Survival Trends With Allogeneic Blood and Marrow Transplantation
Researchers identified areas of improved outcomes for patients receiving allogeneic blood or marrow transplantation as well as some areas of concern.
Graft Vs Host Prophylaxis With Posttransplant Cyclophosphamide Not Associated With Increased Infection Risk
Researchers sought to determine whether GVHD prophylaxis with posttransplant cyclophosphamide following allo-HSCT would be associated with a higher risk of infection.
Posttransplant Cyclophosphamide Safety With Haploidentical Transplantation
Researchers sought to determine if treatment with PTCy is safe for patients with hematologic malignancies in the HLA-haploidentical setting.
- Loading...
Loading...
Next post in SOHO 2021
Loading... 
Loading...